Regeneron Pharmaceuticals Inc (REGN)
Working capital turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 14,202,000 | 13,117,200 | 12,172,900 | 16,071,700 | 8,497,100 |
| Total current assets | US$ in thousands | 18,660,900 | 19,479,200 | 15,884,100 | 14,014,900 | 12,753,900 |
| Total current liabilities | US$ in thousands | 3,944,300 | 3,423,400 | 3,141,300 | 3,932,500 | 2,806,800 |
| Working capital turnover | 0.97 | 0.82 | 0.96 | 1.59 | 0.85 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $14,202,000K ÷ ($18,660,900K – $3,944,300K)
= 0.97
The working capital turnover ratio for Regeneron Pharmaceuticals Inc has shown fluctuations over the years. In 2020, the ratio was 1.19, indicating that the company generated $1.19 in revenue for every dollar of working capital. This ratio improved in 2021 to 1.59, suggesting increased efficiency in utilizing working capital to generate sales.
However, there was a significant decline in the ratio in 2022, dropping to 0.95, which could indicate potential inefficiencies in managing working capital during that period. The ratio further decreased in 2023 to 0.81, indicating a continued decline in revenue generation relative to working capital.
In 2024, there was a slight improvement with the ratio increasing to 0.97, but it still remained below the levels seen in 2020 and 2021. Overall, the working capital turnover ratio for Regeneron Pharmaceuticals Inc has been volatile, suggesting fluctuations in the company's ability to efficiently convert working capital into sales over the years.
Peer comparison
Dec 31, 2024